Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy.
Year: 2021
Type: article
Abstract: Anticancer drugs play an important role in reducing mortality rates and increasing life expectancy in cancer patients. Treatments include monotherapy and/or a combination of radiation therapy, chemotherapy, hormone therapy, or immunotherapy. Despite great advances in drug development, some of these treatments have been shown to induce cardiotoxicity directly affecting heart function and structure, as well as accelerating the development of cardiovascular disease. Such side effects restrict treatment options and can negatively affect disease management. Consequently, when managing cancer patients, it is vital to understand the mechanisms causing cardiotoxicity to better monitor heart function, develop preventative measures against cardiotoxicity, and treat heart failure when it occurs in this patient population. This review discusses the role and mechanism of major chemotherapy agents with principal cardiovascular complications in cancer patients.
Source: Europe PMC (PubMed Central)
DOI: 10.7759/cureus.18194
Institutions: Harlem Hospital Center, California State University Los Angeles, University of California San Diego, Yonsei University, Shanghai First People's Hospital, Northeastern Illinois University, West Coast University, Pontificia Universidad Católica de Valparaíso, University of Iowa, University of Tennessee Health Science Center
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Replacement of Small Animal Echocardiographic Instrumentation, Research Initiative for Scientific Enhancement, MiR-204 regulates type 1 IP3R/Ca2+ axis to control vascular smooth muscle cell contractility and blood pressure: Potential role of the gut microbiome, Training in Cardiovascular Physiology and Pharmacology, UCSD Future Faculty of Cardiovascular Sciences (FOCUS)
OpenAlex ID: W3199130737